deltatrials
Completed PHASE1 NCT06250205

Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib

A Study to Evaluate the Effect of Daily Doses of Obicetrapib Tablets on the Pharmacokinetics of Drospirenone and Ethinyl Estradiol in Healthy Adult Female Subjects

Sponsor: NewAmsterdam Pharma

Conditions Healthy Volunteers
Interventions Drospirenone / Ethinyl Estradiol (COC) Obicetrapib Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)
Updated 4 times since 2024 Last updated: Sep 14, 2024 Started: Feb 5, 2024 Primary completion: Apr 25, 2024 Completion: Apr 26, 2024

Listed as NCT06250205, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by NewAmsterdam Pharma, it has been updated 4 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

4 versions recorded

  1. Oct 2024 — Present [monthly]

    Completed PHASE1

    Status: Recruiting → Completed

  2. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  4. Mar 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

    First recorded

Feb 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NewAmsterdam Pharma
  • Novum
Data source: NewAmsterdam Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Las Vegas, United States